Related Experiment Video
Updated: Dec 3, 2025
07:08
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
5.3K
A Sensitive, Rapid, and Portable CasRx-based Diagnostic Assay for SARS-CoV-2
Daniel J Brogan1, Duverney Chaverra-Rodriguez1, Calvin P Lin2
1Division of Biological Sciences, Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA, 92093.
Medrxiv : the Preprint Server for Health Sciences
|October 27, 2020
Summary
A new CRISPR-based diagnostic, SENSR, rapidly detects SARS-CoV-2 (COVID-19) RNA. This point-of-care test offers a faster, more accessible method for diagnosing infections and combating pandemics.
Area of Science:
- Molecular Biology
- Infectious Diseases
- Biotechnology
Background:
- The COVID-19 pandemic highlighted the urgent need for rapid, accessible diagnostics.
- Current SARS-CoV-2 RNA detection methods are often time-consuming and resource-intensive.
- Point-of-care diagnostics are crucial for controlling infectious disease spread.
Approach:
- Developed SENSR (Sensitive Enzymatic Nucleic-acid Sequence Reporter), a CRISPR-based molecular diagnostic.
- Utilized Cas13d ribonuclease from *Ruminococcus flavefaciens* (CasRx) for SARS-CoV-2 detection.
- Demonstrated detection using both lateral flow and fluorescence assays.
Key Points:
- SENSR effectively detects SARS-CoV-2 sequences in synthetic and patient samples.
- The diagnostic approach is adaptable for emerging pathogens.
- CasRx-based detection offers a sensitive and specific method.
Conclusions:
- SENSR expands the toolkit for point-of-care diagnostics against COVID-19.
- This technology is vital for current pandemic response and future public health preparedness.
- Rapid, adaptable diagnostics are essential for mitigating global health crises.
